- Company
- Betadine, disposes of 3 months of advertising suspension
- by Nho, Byung Chul Apr 8, 2021 05:55am
- Mundipharma's Betadine Throat Spray (Povidone Iodine) was suspended from advertising by the MFDS. Mundipharma recently sent a notice regarding administrative disposition to pharmacies that handle the product, and requested cooperation in the removal of Betadine advertising installations in pharmacies. The advertisement business suspension
- Company
- Zytiga listed as a prostate cancer selective benefit
- by Apr 8, 2021 05:55am
- Janssen announced on the 7th that it will be applied as a first-line treatment for patients with high-risk metastatic prostate cancer with hormone-responsiveness from the 1st. Zytiga, as a CYP17 inhibitor, was approved by the MFDS in July 2012 as a treatment for metastatic castration-resistant prostate cancer, and added hormone-responsive
- Company
- One-on-one briefing sessions with doctors are not allowed
- by Apr 8, 2021 05:55am
- It is expected that MSD Korea will in principle ban one-on-one product presentations for individual doctors from May. Business restrictions are much stronger than the industry's 'fair competition rules'. According to the pharmaceutical industry on the 7th, MSD Korea announced plans to improve CP to its employees on the 5th. From May, it w
- Company
- Tumor-agnostic ‘Rozlytrek’ seeks PE exemption
- by Eo, Yun-Ho Apr 7, 2021 06:03am
- Discussions will begin for the listing of Roche's anticancer drug ‘Rozlytrek,’ which may be prescribed regardless of cancer type if specific conditions are met. According to industry sources, 2 types of anticancer drugs by Roche Korea &8211; Rozlytrek (entrectinib) and Polivy (polatuzumba) &8211; will be up for deliberation by the
- Company
- Beovu heats up the AMD treatment market with its ease of use
- by Apr 7, 2021 06:01am
- Novartis has jumped into the competition in the macular degeneration treatment market with ‘Beovu.’ Emphasizing its longer treatment interval, the new drug is fiercely chasing the market leader ‘Eylea.’ Beovu (brolucizumab) is a treatment for wet (neovascular) age-related macular degeneration (AMD) launched by Novartis as a successo
- Company
- Baculovirus overcomes shortcomings of DNA vaccines
- by Nho, Byung Chul Apr 6, 2021 11:08am
- The development of a COVID-19 ‘DNA and viral vector-based vaccine’ made with 100% domestic technology is well underway. Although in its preclinical stage, the vaccine, once commercialized, is expected to show superior safety and protection over existing COVID-19 vaccines by Pfizer, Moderna, AstraZeneca as well as vaccines from Russia an
- Company
- The Cancer Committee discusses Tagrisso's first-line therapy
- by Eo, Yun-Ho Apr 6, 2021 06:10am
- Tagrisso, a third-generation lung cancer targeting anticancer drug, is once again discussed at the Cancer Drugs Benefit Appraisal Committee in about a year. According to related industries, discussions on expanding the benefits of first-line therapy for the third-generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI
- Company
- Janssen’s ‘Tremfya’ approved for psoriatic arthritis
- by Apr 6, 2021 06:08am
- Janssen Pharmaceutical Companies of Johnson & Johnson announced on the 5th that the Korean Ministry of Food and Drug Safety (MFDS) approved its psoriatic arthritis treatment ‘Tremfya (guselkumab)’ on March 29th. With the approval, Tremfya may now be used for the treatment of adult patients with active psoriatic arthritis (PsA) who ha
- Company
- Reimbursement expanded for Takeda’s Adcetris and Alunbrig
- by Eo, Yun-Ho Apr 6, 2021 06:08am
- Takeda Korea has achieved continuous success in expanding reimbursement for its anticancer drugs, increasing the company’s hold over the market. According to industry sources, starting from April 1st, the government has decided to grant reimbursement for Takeda Korea’s antibody-drug conjugate ‘Adcetris (brentuximab vedotin)’ as a firs
- Company
- SK Biopharm's new epilepsy drug licensed in Europe
- by An, Kyung-Jin Apr 6, 2021 06:08am
- SK Biopharmaceuticals announced on the 31st that Cenobamate, a new epilepsy drug, has obtained sales permission from the EC on the 30th (local time). It has been about two months since it received a recommendation for marketing approval from CHMP under the European Medicines Agency (EMA) last month. Through this sales permit, SK Biopharm has
